May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.
Ending the HIV Epidemic Is a Team Effort. The New York City and State Health Departments Discuss Their Combined Work
Johanne Morne, M.S., and Oni Blackstock, M.D., sat down with TheBody to discuss their successes and their work to close the disparities gap.
Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.
Though not as widely studied, there are many ways that men who belong to the gay family networks of the ballroom scene may be getting an HIV intervention.
This population is under-represented in HIV data, and few prevention or treatment interventions exist to support them. A new meta-analysis hopes to paint a picture of what's needed.
But other research links prisons themselves to mental health challenges and infectious disease outbreaks.
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
Will potential study participants choose a vaccine trial over getting access to PrEP?
June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.
Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.